Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2572 - Extended RAS and BRAF mutation analysis of circulating tumor DNA in patients with biliary tract cancer


08 Oct 2016


Poster Display


Lars Henrik Jensen


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


L.H. Jensen1, R.F. Andersen2, A. Jakobsen1

Author affiliations

  • 1 Oncology, Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, 7100 - Vejle/DK
  • 2 Clinical Biochemistry, Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, 7100 - Vejle/DK


Abstract 2572


Clinical trials have failed to show benefit from adding anti-EGFR antibodies to chemotherapy in the systemic treatment of biliary tract cancer with respect to progression free and overall survival, but a trend towards higher response rate. In colorectal cancer, effect of anti-EGFR therapy is restricted to patients with RAS and BRAF wild-type tumors. Mutation analysis of circulating DNA may be a clinically applicable method for serial analyses. The purpose of this early cancer biomarker study was to evaluate the feasibility of extended RAS and BRAF mutation analysis of cell free DNA in blood derived from patients with metastatic biliary tract cancer.


Patients with KRAS exon 2 codons 12/13 wild type metastatic biliary tract cancer and available blood samples were included. DNA was isolated from 4 ml plasma, pre-amplified and analyzed using Droplet Digital PCR. Adequate positive and negative controls were included. The extended RAS and BRAF analysis covered a total of 27 mutations in KRAS exons 3/4, NRAS exon 2/3 and BRAF V600E.


A total of 52 patients were included. In 12 patients (23.1%), a mutation was found; BRAF n = 4, KRAS n = 4 and NRAS n = 4. Except for one patient with a NRAS mutation in plasma and wild-type in tumor, tumor biopsies harbored an identical mutation.


Extended RAS and BRAF mutation analysis in cell free DNA from blood derived from patients with metastatic biliary tract cancer was feasible. The fraction of mutations was 23.1% and equally distributed in KRAS, NRAS and BRAF. The high frequency of mutations beyond KRAS exon 2 may explain the lacking effect of EGFR inhibition in previous studies and justify extended mutation analysis.

Clinical trial identification


Legal entity responsible for the study

Lars Henrik Jensen


Lillebaelt Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings